AU2003294220A1 - Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES - Google Patents

Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Info

Publication number
AU2003294220A1
AU2003294220A1 AU2003294220A AU2003294220A AU2003294220A1 AU 2003294220 A1 AU2003294220 A1 AU 2003294220A1 AU 2003294220 A AU2003294220 A AU 2003294220A AU 2003294220 A AU2003294220 A AU 2003294220A AU 2003294220 A1 AU2003294220 A1 AU 2003294220A1
Authority
AU
Australia
Prior art keywords
key
antigenic epitope
peptide vaccines
hybrid peptide
epitope hybrid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003294220A
Other languages
English (en)
Other versions
AU2003294220A8 (en
Inventor
Robert E. Humphreys
Minzhen Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Antigen Express Inc
Original Assignee
Antigen Express Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/245,871 external-priority patent/US20030235594A1/en
Priority claimed from US10/253,286 external-priority patent/US7179645B2/en
Application filed by Antigen Express Inc filed Critical Antigen Express Inc
Publication of AU2003294220A8 publication Critical patent/AU2003294220A8/xx
Publication of AU2003294220A1 publication Critical patent/AU2003294220A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2003294220A 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES Abandoned AU2003294220A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10/245,871 2002-09-17
US10/245,871 US20030235594A1 (en) 1999-09-14 2002-09-17 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/253,286 US7179645B2 (en) 2002-09-24 2002-09-24 Ii-Key/antigenic epitope hybrid peptide vaccines
US10/253,286 2002-09-24
PCT/US2003/028574 WO2004030616A2 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Publications (2)

Publication Number Publication Date
AU2003294220A8 AU2003294220A8 (en) 2004-04-23
AU2003294220A1 true AU2003294220A1 (en) 2004-04-23

Family

ID=32072825

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003294220A Abandoned AU2003294220A1 (en) 2002-09-17 2003-09-12 Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES

Country Status (5)

Country Link
EP (1) EP1556072B1 (https=)
JP (1) JP2006515744A (https=)
AU (1) AU2003294220A1 (https=)
CA (1) CA2499123A1 (https=)
WO (1) WO2004030616A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601351B1 (en) 2002-06-26 2009-10-13 Human Genome Sciences, Inc. Antibodies against protective antigen
CA2571168A1 (en) * 2004-06-17 2006-01-26 Mannkind Corporation Mhc i-binding ssx-241-49 variants
AU2006261342B2 (en) 2005-06-15 2012-02-02 The Ohio State University Research Foundation Her-2 peptides
US20080095798A1 (en) * 2006-10-18 2008-04-24 Robert Humphreys Ii-key enhanced vaccine potency
GB0706070D0 (en) * 2007-03-28 2007-05-09 Scancell Ltd Nucleic acids
US20100234283A1 (en) 2009-02-04 2010-09-16 The Ohio State University Research Foundation Immunogenic epitopes, peptidomimetics, and anti-peptide antibodies, and methods of their use
JP2012050440A (ja) * 2011-09-16 2012-03-15 Chiba Univ ヒトＴｈ１／Ｔｈ２分化誘導の評価方法
PL2914286T3 (pl) * 2012-10-30 2022-01-31 Aravax Pty Ltd Nowe cząsteczki immunoterapeutyczne oraz ich zastosowania
WO2015042664A1 (en) 2013-09-25 2015-04-02 Monash University Novel immunotherapeutic composition and uses thereof
LT3388075T (lt) * 2015-03-27 2023-11-10 Immatics Biotechnologies Gmbh Nauji peptidai ir peptidų deriniai, skirti naudoti imunoterapijai prieš įvairius navikus (seq id 25 - mrax5-003)
GB201507030D0 (en) * 2015-04-24 2015-06-10 Immatics Biotechnologies Gmbh Immunotherapy against lung cancers, in particular NSCLC
BR112018071466A2 (pt) * 2016-04-19 2019-03-19 Imcyse Sa novos peptídeos de ligação a cd1d imunogênicos
CN108129558B (zh) * 2017-12-21 2021-10-12 中国医学科学院北京协和医院 一种桦树花粉主要致敏蛋白Bet v 8的提取和分离纯化方法及应用
US20230000908A1 (en) * 2019-09-11 2023-01-05 Ohio State Innovation Foundation Engineered cells and uses thereof
WO2023240295A2 (en) * 2022-06-10 2023-12-14 Ayass Bioscience Llc Food allergen processing and desensitization by aptamers

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
DE3586772T2 (de) 1984-07-24 1993-03-04 Coselco Mimotopes Pty Ltd Verfahren zur bestimmung von mimotopen.
US4797368A (en) 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US6133029A (en) 1988-03-21 2000-10-17 Chiron Corporation Replication defective viral vectors for infecting human cells
US5194425A (en) 1988-06-23 1993-03-16 Anergen, Inc. Mhc-mediated toxic conjugates useful in ameliorating autoimmunity
ATE123780T1 (de) 1989-02-17 1995-06-15 Chiron Mimotopes Pty Ltd Verfahren zur verwendung und herstellung von peptiden.
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5126132A (en) 1989-08-21 1992-06-30 The United States Of America As Represented By The Department Of Health And Human Services Tumor infiltrating lymphocytes as a treatment modality for human cancer
JP3203599B2 (ja) 1989-10-24 2001-08-27 カイロン コーポレイション 感染性タンパク質デリバリーシステム
US5747334A (en) 1990-02-15 1998-05-05 The University Of North Carolina At Chapel Hill Random peptide library
AU668347B2 (en) 1990-11-21 1996-05-02 Torrey Pines Institute For Molecular Studies Synthesis of equimolar multiple oligomer mixtures, especially of oligopeptide mixtures
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
JPH07501942A (ja) 1991-11-29 1995-03-02 カイロン　コーポレイション 抗ガン免疫療法用ベクター構成体
US5679527A (en) 1992-03-25 1997-10-21 Antigen Express, Inc. Modification of polypeptide structure
WO1994012520A1 (en) 1992-11-20 1994-06-09 Enzon, Inc. Linker for linked fusion polypeptides
US5559028A (en) 1993-05-19 1996-09-24 Antigen Express, Inc. Methods of enhancing or antigen presentation to T cells inhibiting
EP0726941B1 (en) 1993-08-06 2002-04-03 Epimmune Inc. Methods for (ex vivo) therapy using peptide-loaded antigen presenting cells for the activation of ctl
US5874214A (en) 1995-04-25 1999-02-23 Irori Remotely programmable matrices with memories
US5910300A (en) 1995-11-01 1999-06-08 Bracco Research S.A. Amphiphilic linkers for coupling administrable diagnostically or physiologically active agents and bioselective targeting compounds
AU3307497A (en) 1996-06-26 1998-01-14 Antigen Express, Inc. Immunotherapy by modulation of antigen presentation
US6432409B1 (en) * 1999-09-14 2002-08-13 Antigen Express, Inc. Hybrid peptides modulate the immune response

Also Published As

Publication number Publication date
CA2499123A1 (en) 2004-04-15
WO2004030616A3 (en) 2004-10-07
EP1556072A4 (en) 2005-12-21
AU2003294220A8 (en) 2004-04-23
EP1556072A2 (en) 2005-07-27
WO2004030616A2 (en) 2004-04-15
EP1556072B1 (en) 2010-05-19
JP2006515744A (ja) 2006-06-08

Similar Documents

Publication Publication Date Title
GB2463586B (en) li-key/antigenic epitope hybrid peptide vaccines
AU2003299535A1 (en) Group b streptococcus vaccine
IL176006A0 (en) Immunogenic peptide carrier conjugates and methods for producing the same
PT1801219E (pt) Péptidos antigénicos de neisseria
AU2003294220A1 (en) Ii-KEY/ANTIGENIC EPITOPE HYBRID PEPTIDE VACCINES
EP1572918A3 (en) Synthetic glyco-lipo-peptides as vaccines
AU2003207459A1 (en) Cancer-associated epitope
IL165661A0 (en) Liposomal vaccine
EP1558628A4 (en) ANTIGENIC PEPTIDES
AU2003203002A1 (en) Polymeric conjugates for delivery of mhc-recognized epitopes via peptide vaccines
AU2003264724A1 (en) Flagellin peptides as adjuvants for vaccines
AU2003228863A1 (en) Immunogenic peptides
AU2003229199A1 (en) Liposome vaccine formulations for fin-fish
AU2003283963A1 (en) Mage-c2 antigenic peptides and uses thereof
AU2001251394A1 (en) Immunological methodology for discerning human papillomavirus
AU2003221110A1 (en) Mucosal immune vaccine for periodontal diseases
AU2002952524A0 (en) Epstein barr virus peptide epitopes
AU2002365187A1 (en) Epitope synchronization in antigen presenting cells
AU2001245552A1 (en) Transcutaneous immunization for large particulate antigens
AU2003900767A0 (en) Idiotypic vaccine
AU2003276846A1 (en) Thrombopoiesis-stimulating proteins having reduced immunogenicity
AU2002303093A1 (en) Mycobacterial vaccines
GB0313064D0 (en) Mycobacterial vaccine
AU2003232739A1 (en) Ebv vaccine using gp350 antigen
AUPR975401A0 (en) Antigenic polypeptide

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase